BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains a Market Perform rating on Bristol-Myers Squibb and raises the price target from $53 to $57.
November 01, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has maintained its Market Perform rating on Bristol-Myers Squibb and increased the price target from $53 to $57, indicating a positive outlook.
The increase in the price target from $53 to $57 by BMO Capital suggests a positive outlook for Bristol-Myers Squibb, which could lead to a short-term increase in stock price. The Market Perform rating indicates a neutral stance, but the raised target shows improved expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100